Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle

Journal of Vascular Surgery

Volumn 31, Issue 5, 2000, Pages 944-952

  Pipinos, Iraklis I ^a,b   Shepard, Alexander D ^a,b   Anagnostopoulos, Petros V ^a,b   Katsamouris, Asterios ^a,b   Boska, Michael D ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOENERGY; CLAUDICATION; CONTROLLED STUDY; ENERGY METABOLISM; EXERCISE TEST; HUMAN; MUSCLE DISEASE; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SKELETAL MUSCLE; TREADMILL EXERCISE;

EID: 0034079848     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2000.106421     Document Type: Article

References (37)

1. Heintz SE, Bone GE, Slaymaker EE, Hayes AC, Barnes RW. Value of arterial pressure measurements in the proximal and distal part of the thigh in arterial occlusive disease. Surg Gynecol Obstet 1978;146:337-43.
2. Marbini A, Gemignani F, Scoditti U, Rustichelli P, Bragaglia MM, Govoni E. Abnormal muscle mitochondria in ischemic claudication. Acta Neurol Belg 1986;86:304-10.
3. Farinon AM, Marbini A, Gemignani F, Govoni E, Bragaglia MM, Sianesi M, et al. Skeletal muscle and peripheral nerve changes caused by chronic arterial insufficiency. Clin Neuropathol 1984;3:240-52.
4. Makitie J, Teravainen H. Histochemical changes in striated muscle in patients with intermittent claudication. Arch Pathol Lab Med 1977;101:658-63.
5. Bhat HK, Hiatt WR, Hoppel CL, Brass EP. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation 1999;99:807-12.
6. Wang H, Hiatt WR, Barstow TJ, Brass EP. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. Eur J Appl Physiol 1999;80:22-7.
7. Argov Z, Bank WJ. Phosphorus magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders. Ann Neurol 1991;30:90-7.
8. Chance B. Applications of 31P NMR to clinical biochemistry. Ann N Y Acad Sci 1984;428:318-32.
9. Boska MD, Nelson JA, Sripathi N, Pipinos II, Shepard AD, Welch KM. 31P MRS studies of exercising human muscle at high temporal resolution. Magn Reson Med 1999;41:1145-51.
10. 31P MRS. Magn Reson Med 1994;32:1-10.
11. Haase A, Leibfritz D, Werk W. 31P FLASH NMR imaging. Magn Reson Med 1988;7:358-63.
12. Moon RB, Richards JH. Determination of intracellular pH by 31P magnetic resonance. J Biol Chem 1973;248:7276-8.
13. 31P NMR. Magn Reson Med 1984;1:307-15.
14. Wolf EA Jr, Sumner DS, Strandness DE Jr. Correlation between nutritive blood flow and pressure in limbs of patients with intermittent claudication. Surg Forum 1972;23:238-9.
15. Hiatt WR. Introduction and overview, and medical treatment of claudication. In: Hirsch AT, Hiatt WR, editors. An office based approach to the diagnosis and treatment of peripheral arterial disease, part IV. The American Journal of Medicine educational series; 1999. p 3-15.
16. Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, Gabriel S. The sensitivity specificity and predictive value of traditional clinical evaluation of peripheral arterial disease: results from non-invasive testing in a defined population. Circulation 1985;71:516-22.
17. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991 Jun;20(2):384-92.
18. Hiatt WR, Nawaz D, Regensteiner JG, Hossack KF. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil 1988; 12:525-32.
19. Pernow B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. Scand J Clin Lab Invest 1968;21:277-87.
20. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology 1993;44:1-10.
21. Zatina MA, Berkowitz HD, Gross GM, Maris JM, Chance B. 31P nuclear magnetic resonance spectroscopy: noninvasive biochemical analysis of the ischemic extremity. J Vasc Surg 1986;3:411-20.
22. Kemp GJ, Hands LJ, Ramaswami G, Taylor DJ, Nicolaides A, Amato A, et al. Calf muscle mitochondrial and glycogenolytic ATP synthesis in patients with claudication due to peripheral vascular disease analysed using 31P magnetic resonance spectroscopy. Clin Sci (Colch) 1995;89:581-90.
23. Hands LJ, Bore PJ, Galloway G, Morris PJ, Radda GK. Muscle metabolism in patients with peripheral vascular disease investigated by 31P nuclear magnetic resonance spectroscopy. Clin Sci 1986;71:283-90.
24. Kemp GJ, Taylor DJ, Thompson CH, Hands LJ, Rajagopalan B, Styles P, et al. Quantitative analysis by 31P magnetic resonance spectroscopy of abnormal mitochondrial oxidation in skeletal muscle during recovery from exercise. NMR Biomed 1993;6:302-10.
25. Williams DM, Fencil L, Chenevert TL. Peripheral arterial occlusive disease: P-31 MR spectroscopy of calf muscle. Radiology 1990;175:381-5.
26. Van der Grond J, Crolla RM, Ten Hove W, van Vroonhoven TJ, Mali WP. Phosphorus magnetic resonance spectroscopy of the calf muscle in patients with peripheral arterial occlusive disease. Invest Radiol 1993;28:104-8.
27. Wahl DG, Simon JP, Robin B, Walker P, Jouanny P, Escanye JM, et al. Phosphorus magnetic resonance spectroscopy: a non-invasive technique for the study of occlusive arterial leg disease and peripheral vasodilator therapy. Angiology 1994;45:367-76.
28. Schunk K, Romaneehsen B, Rieker O, Duber C, Kersjes W, Schadmand-Fischer S, et al. Dynamic phosphorus-31 magnetic resonance spectroscopy in arterial occlusive disease: effects of vascular therapy on spectroscopic results. Invest Radiol 1998;33:329-35.
29. Jansson E, Johansson J, Sylven C, Kaijser L. Calf muscle adaptation in intermittent claudication. Side-differences in muscle metabolic characteristics in patients with unilateral arterial disease. Clin Physiol 1988;8:17-29.
30. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992;73:346-53.
31. Lundgren F, Dahllof AG, Schersten T, Bylund-Fellenius AC. Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaptation, effect of different treatments and consequences on walking performance. Clin Sci 1989;77:485-93.
32. Bylund AC, Hammarsten J, Holm J, Schersten T. Enzyme activities in skeletal muscles from patients with peripheral arterial insufficiency. Eur J Clin Invest 1976;6:425-9.
33. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 1987;62:2383-7.
34. Brass EP. Skeletal muscle metabolism as a target for drug therapy in peripheral arterial disease. Vasc Med 1996;1:55-9.
35. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66-72.
36. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
37. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-6.